<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Deep venous thombosis and pulmonary embolism MeG-CLS-055</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="deep-vein-thrombosis-and-pulmonary-embolism">Deep Vein Thrombosis and Pulmonary Embolism</h1>
<h2 id="executive-summary">Executive summary</h2>
<h2 id="introduction">Introduction</h2>
<p>Deep venous thrombosis (DVT) and pulmonary embolism (PE) are both manifestations of venous thromboembolism. DVT can be defined as the formation of a blood clot (thrombus) within a deep vein, with the most common site of affectation being the lower limbs. PE, on the other hand, is a potentially life-threatening complication of DVT in which the thrombus formed becomes dislodged and migrates to occlude an artery within the lung.</p>
<h2 id="target-users">Target users</h2>
<ul>
<li><p>Nurses</p></li>
<li><p>Doctors</p></li>
</ul>
<p><strong>Target area of use</strong></p>
<ul>
<li><p>Gate Clinic</p></li>
<li><p>Outpatient Department</p></li>
<li><p>Ward</p></li>
</ul>
<h2 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h2>
<p>This guideline provides information on the diagnosis and treatment of deep vein thrombosis and pulmonary embolism. A large proportion of patients with pulmonary embolism are asymptomatic. History and examination should seek for risk factures and clinical features of these conditions. The Wells scoring systems should be used to assess clinical probability of DVT and PE respectively. Patients should be initially managed on the ward with heparin, warfarin (non-pregnant patients only) and supportive care. Anticoagulation status should be reviewed using coagulation studies. Warfarin if used should be given for at least 3 months.</p>
<h2 id="limitations">Limitations</h2>
<p>Facilities for monitoring and treating venous thromboembolism are not available at Keneba and Basse. Patients presenting there with these conditions should be stabilized and referred.</p>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<p>Risk factors for venous thromboembolism should be ruled out.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Malignancy</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Prolonged bed rest</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Smoking</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Stroke</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Obesity</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Pregnancy</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Recent long-distance travel</p>
</div></li>
</ul>
<p>Symptoms and signs of DVT usually occur distal to the site of venous occlusion and include:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Pain in affected limb: occurs in about 50% of cases</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Limb swelling: most specific symptom. DVT should be ruled out in all patients presenting with unilateral pedal swelling</p>
</div></li>
</ul>
<p>In as many as 40% of patients, PE is silent without obvious symptoms. Those who are symptomatic may present with sudden onset of:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Shortness of breath</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Chest pain worse on inspiration</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Haemoptysis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Cough</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Syncope</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Death</p>
</div></li>
</ul>
<h2 id="examination-findings">Examination findings</h2>
<p>In suspected DVT, a general examination should be carried out, followed by examination of the affected limb. Presence of any of the following should raise suspicion of the presence of a DVT.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Unilateral pitting oedema</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Homans sign: calf pain on foot dorsiflexion with the knee extended</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Pratt sign: Tenderness over calf muscle on palpation</p>
</div></li>
</ul>
<p>PE may present with:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Deranged vitals:</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Low saturation of oxygen</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Tachypnoea</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Tachycardia</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hypotension</p>
</div></li>
</ul>
<p>Chest examination</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Maybe normal in the majority of patients.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Occasionally, a pleural friction rub may be heard over the affected area</p>
</div></li>
</ul>
<p>Cardiovascular examination (may be normal apart from tachycardia):</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Parasternal heave</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Loud pulmonary component of the second heart sound</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Raised jugular venous pressure</p>
</div></li>
</ul>
<h3 id="wells-scores">Wells scores</h3>
<p>If the diagnosis of DVT is suspected following history and physical examination, the two-level DVT Wells score should be used to estimate the clinical probability of DVT.</p>
<p><em>Two-Level DVT Wells Score</em></p>
<table>
<thead>
<tr class="header">
<th><strong>Clinical Feature</strong></th>
<th><strong>Points</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Active cancer (treatment ongoing, within 6 months or palliative)</td>
<td>1</td>
</tr>
<tr class="even">
<td>Paralysis, paresis or recent plaster immobilization of the lower extremities</td>
<td>1</td>
</tr>
<tr class="odd">
<td>Recently bedridden for 3 days or more or major surgery within 12 weeks requiring general or regional anaesthesia</td>
<td>1</td>
</tr>
<tr class="even">
<td>Localized tenderness along the distribution of the deep venous system</td>
<td>1</td>
</tr>
<tr class="odd">
<td>Entire leg swollen</td>
<td>1</td>
</tr>
<tr class="even">
<td>Calf swelling at least 3 cm larger than asymptomatic side</td>
<td>1</td>
</tr>
<tr class="odd">
<td>Pitting oedema confined to the symptomatic leg</td>
<td>1</td>
</tr>
<tr class="even">
<td>Collateral superficial veins (non-varicose)</td>
<td>1</td>
</tr>
<tr class="odd">
<td>Previously documented DVT</td>
<td>1</td>
</tr>
<tr class="even">
<td>Alternative diagnosis at least as likely as a DVT</td>
<td>-2</td>
</tr>
</tbody>
</table>
<p><em>Interpretation:</em></p>
<table>
<thead>
<tr class="header">
<th>DVT Likely</th>
<th>2 Points Or More</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>DVT Unlikely</td>
<td>1 Point Or Less</td>
</tr>
</tbody>
</table>
<p>If the diagnosis of PE is suspected following history and physical examination, the two-level PE Wells score should be used to estimate the clinical probability of PE.</p>
<p><em>Two-Level PE Well’s Score</em></p>
<table>
<thead>
<tr class="header">
<th><strong>Clinical Feature</strong></th>
<th><strong>Points</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Clinical signs and symptoms of DVT (minimum of leg swelling and pain with palpation of the deep veins)</td>
<td>3</td>
</tr>
<tr class="even">
<td>An alternative diagnosis is less likely than PE</td>
<td>3</td>
</tr>
<tr class="odd">
<td>Heart rate &gt; 100 beats per minute</td>
<td>1.5</td>
</tr>
<tr class="even">
<td>Immobilisation for more than 3 days or surgery in the previous 4 weeks</td>
<td>1.5</td>
</tr>
<tr class="odd">
<td>Previous DVT/PE</td>
<td>1.5</td>
</tr>
<tr class="even">
<td>Haemoptysis</td>
<td>1</td>
</tr>
<tr class="odd">
<td>Malignancy (on treatment, treated in the last 6 months, or palliative)</td>
<td>1</td>
</tr>
</tbody>
</table>
<p><em>Interpretation:</em></p>
<table>
<thead>
<tr class="header">
<th>PE Likely</th>
<th>More Than 4 Points</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>PE Unlikely</td>
<td>4 Points Or Less</td>
</tr>
</tbody>
</table>
<h2 id="differential-diagnoses">Differential diagnoses</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Cellulitis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Lymphoedema</p>
</div></li>
</ul>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Soft tissue injury</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Dependent oedema</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Congestive cardiac failure</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Renal failure</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nephritic syndrome</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Swelling in a paralysed limb</p>
</div></li>
</ul>
<h2 id="investigations">Investigations</h2>
<p>All patients with suspected DVT should be offered:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doppler ultrasonography: to confirm the presence of a clot</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Coagulation studies: INR, PT, APTT to investigate for hypercoagulability if indicated.</p>
</div></li>
</ul>
<p>In suspected PE, the following should be done:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>CXR: findings might include: Enlarged pulmonary artery (Fleischner sign), peripheral wedge of airspace opacity which implies lung infarction (Hampton’s Hump), regional oligaemia (Westermark sign) or <a href="https://radiopaedia.org/articles/pleural-effusion">pleural effusion</a> </p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>ECG: May show sinus tachycardia (most common), right heart strain pattern: seen as a right bundle branch block pattern or right axis deviation or S<sub>I</sub>Q<sub>III</sub>T<sub>III</sub> pattern: this refers to a deep S wave in lead I, Q wave and T wave inversion in lead III</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Echocardiography: Right ventricular wall hypokinesis, right ventricular dilatation, and pulmonary artery hypertension may be seen</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>INR: Done to get baseline value before the commencement of warfarin therapy</p>
</div></li>
</ul>
<h2 id="management">Management </h2>
<h3 id="management-in-gate-clinic">Management in Gate Clinic</h3>
<p>All patients with features of a DVT or PE should be referred immediately to the ward for urgent review by a doctor.</p>
<h3 id="management-on-the-ward">Management on the Ward</h3>
<p>In suspected acute PE, commence intravenous fluid and oxygen (if oxygen saturation &lt; 88%).</p>
<p>Heparin and warfarin should be started as soon as possible for prophylaxis in high-risk patients or treatment after confirmed DVT or PE. Heparin should be continued for at least 5 days or until 2 consecutive target INR results are obtained. In pregnancy, only heparin is used</p>
<p>Unfractionated heparin can be given subcutaneously as 250 units/kg stat then every 12 hours. It is the preferred option in patients with kidney disease. Enoxaparin can be given subcutaneously as 1.5 mg/kg/dose OD.</p>
<p>Monitor APTT (ideally, every 6 hours) and adjust unfractionated heparin dose accordingly.</p>
<p>Warfarin can be initiated with a once-daily dose between 2 mg and 5 mg. The maintenance dose of warfarin is usually between 2 mg and 10 mg once daily.</p>
<p>Daily INR monitoring should start from day 3 of initiation of therapy until INR is at target for more than 2 consecutive readings.</p>
<table>
<thead>
<tr class="header">
<th><strong>Condition</strong></th>
<th><strong>Target INR</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>DVT prophylaxis</td>
<td>2 – 2.5</td>
</tr>
<tr class="even">
<td>DVT or PE treatment</td>
<td>2 – 3</td>
</tr>
</tbody>
</table>
<p>Thereafter, the frequency of INR monitoring is twice weekly but can be reduced gradually to once-weekly, once every 2 weeks, and then once monthly as long as the patient’s INR remains within the therapeutic range. Warfarin doses should be adjusted according to the INR results. More frequent monitoring is needed after any dose adjustment until stable readings are obtained.</p>
<p>Warfarin should be continued for at least 3 months. Warfarin therapy should be extended beyond 3 months for patients with unprovoked proximal DVT or PE if their risk of recurrence is high and there is no additional risk of major bleeding.</p>
<p>Paracetamol can be prescribed for pain in DVT</p>
<p><strong>Key Issues for Nursing care</strong></p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Monitor vital signs every hour initially in acute PE. This frequency may be reduced to every 4 hours as patient stabilizes.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Monitor vital signs once every shift in DVT.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nurse with affected leg elevated</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Avoid IM injections on the affected limb</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Strict fluid charts</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ensure enoxaparin is given at the same time every day.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Be wary of heparin concentrations when calculating doses</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Call the doctor if:</p>
</div></li>
</ul>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Temperature &gt; 38.5ºC</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Pulse &lt; 50 or &gt; 120 bpm</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Systolic blood pressure &lt; 90 or &gt; 160 mmHg</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Diastolic blood pressure &lt; 60 or &gt; 90 mmHg</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Oxygen saturation &lt; 90%</p>
</div></li>
</ul>
<h2 id="references">References</h2>
<p>NICE Guidance for Venous Thromboembolic Diseases <a href="https://www.nice.org.uk/guidance/cg144/chapter/recommendations#diagnosis-2">https://www.nice.org.uk/guidance/cg144/chapter/recommendations#diagnosis-2</a></p>
<p>Aggarwal V, Nicolais CD, Lee A; Bashir R. et al. Acute management of pulmonary embolism. <a href="https://www.acc.org/latest-in-cardiology/articles/2017/10/23/12/12/acute-management-of-pulmonary-embolism">https://www.acc.org/latest-in-cardiology/articles/2017/10/23/12/12/acute-management-of-pulmonary-embolism</a></p>
<p>Medscape. Pulmonary Embolism <a href="https://emedicine.medscape.com/article/300901-overview">https://emedicine.medscape.com/article/300901-overview</a></p>
<p>Diagnosis and Management of Acute Deep Vein Thrombosis: A Joint Consensus Document From the European Society of Cardiology Working Groups of Aorta and Peripheral Circulation and Pulmonary Circulation and Right Ventricular Function. Eur Heart J 2017; Feb 17:[Epub ahead of print].</p>
<p>Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl 2).</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Azeezat Sallahdeen</th>
<th>Date: 24 November 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Fatai Akemokwe</td>
<td>Date: 30 January 2019</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td>31 January 2021</td>
</tr>
<tr class="even">
<td>1.1</td>
<td>Executive summary added</td>
<td>31 January 2021</td>
</tr>
<tr class="odd">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
